Formycon Wins Endorsement For Second EU Lucentis Rival

CHMP Positive Opinion For Ranivisio Sets Up Approval For Ranibizumab Biosimilar

 
• By David Wallace
EU Flag Eye Close-Up
Formycon’s biosimilar is the second approved EU rival to Lucentis • Source: Shutterstock

More from Biosimilars

More from Products